FR05C0047I1 - - Google Patents

Info

Publication number
FR05C0047I1
FR05C0047I1 FR05C0047C FR05C0047I1 FR 05C0047 I1 FR05C0047 I1 FR 05C0047I1 FR 05C0047 C FR05C0047 C FR 05C0047C FR 05C0047 I1 FR05C0047 I1 FR 05C0047I1
Authority
FR
France
Prior art keywords
ones
pyran
retrovirus
hydroxy
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR05C0047I1 publication Critical patent/FR05C0047I1/fr
Application granted granted Critical
Publication of FR05C0047I2 publication Critical patent/FR05C0047I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR05C0047C 1994-05-06 2005-12-22 Active FR05C0047I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23881794A 1994-05-06 1994-05-06
US34936194A 1994-12-02 1994-12-02
PCT/US1995/005219 WO1995030670A2 (en) 1994-05-06 1995-05-04 Pyranone compounds useful to treat retroviral infections

Publications (2)

Publication Number Publication Date
FR05C0047I1 true FR05C0047I1 (enExample) 2006-03-10
FR05C0047I2 FR05C0047I2 (enExample) 2007-10-19

Family

ID=26931995

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0047C Active FR05C0047I2 (enExample) 1994-05-06 2005-12-22

Country Status (32)

Country Link
US (2) US5852195A (enExample)
EP (1) EP0758327B1 (enExample)
JP (1) JP3883206B2 (enExample)
KR (1) KR100445929B1 (enExample)
CN (2) CN1329378C (enExample)
AT (1) ATE236894T1 (enExample)
AU (2) AU701965B2 (enExample)
BR (1) BR9507615A (enExample)
CA (2) CA2187523C (enExample)
CO (1) CO4810313A1 (enExample)
CZ (1) CZ296515B6 (enExample)
DE (2) DE69530294T2 (enExample)
DK (1) DK0758327T3 (enExample)
ES (1) ES2192201T3 (enExample)
FI (1) FI117387B (enExample)
FR (1) FR05C0047I2 (enExample)
HU (1) HU228057B1 (enExample)
IL (3) IL129871A (enExample)
LU (1) LU91220I2 (enExample)
MX (1) MX9605391A (enExample)
MY (2) MY127701A (enExample)
NL (1) NL300216I2 (enExample)
NO (2) NO315799B1 (enExample)
NZ (1) NZ285510A (enExample)
PE (1) PE23196A1 (enExample)
PL (1) PL190540B1 (enExample)
PT (1) PT758327E (enExample)
RU (1) RU2139284C1 (enExample)
SI (1) SI0758327T1 (enExample)
SK (1) SK284407B6 (enExample)
TW (1) TW504507B (enExample)
WO (1) WO1995030670A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
PT909184E (pt) * 1996-07-03 2004-02-27 Upjohn Co Libertacao de farmaco para um alvo utilizando derivados de sulfonamida
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
NZ502569A (en) * 1997-07-29 2002-05-31 Upjohn Co Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4
NZ502566A (en) 1997-07-29 2002-03-28 Upjohn Co Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation containing a pyranone and a basic amine
BR9810866B1 (pt) * 1997-07-29 2010-07-13 composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos.
CN100471832C (zh) * 1997-09-11 2009-03-25 法玛西雅厄普约翰美国公司 用于制备蛋白酶抑制剂的化合物
DK1161427T3 (da) * 1999-03-18 2003-02-24 Upjohn Co Forbedret fremgangsmåde til asymmetrisk hydrogenering
US6956048B2 (en) * 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
EP1917958B1 (en) 2000-01-19 2012-06-13 Abbott Laboratories Improved HIV protease inhibitors pharmaceutical formulations
FI113942B (fi) * 2000-08-18 2004-07-15 Control Ox Oy Kasviperäisten fenolisten yhdisteiden käyttö valmistettaessa klamydiainfektion hoidossa ja ennaltaehkäisyssä käyttökelpoista farmaseuttista valmistetta, terveyteen myönteisesti vaikuttavaa ravintoainekoostumusta tai koostumusta lisättäväksi tällaisiin elintarvikkeisiin
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
CN100358891C (zh) * 2002-02-25 2008-01-02 库多斯药物有限公司 可用作atm抑制剂的吡喃酮
MXPA04009672A (es) * 2002-04-01 2004-11-12 Pfizer Inhibidores de la rna polimerasa dependiente del rna del virus de la hepatitis c, y las composiciones y los tratamientos que usan los mismos.
RU2234535C2 (ru) * 2002-10-03 2004-08-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Субстрат для определения активности интегразы вируса иммунодефицита человека
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
IL161586A (en) * 2004-04-22 2015-02-26 Rafael Advanced Defense Sys Irreplaceable energetic material and reactive shielding that uses it
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
US20060135562A1 (en) * 2004-11-16 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and darunavir
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
CA2583195A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
US20060160859A1 (en) * 2004-12-01 2006-07-20 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW873140
US20060135563A1 (en) * 2004-12-01 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and SCH-417690
WO2006060159A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
CN102816111B (zh) 2007-03-12 2014-08-06 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US20090062346A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched tipranavir
JP2010540517A (ja) * 2007-09-25 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害剤
KR101076680B1 (ko) * 2007-11-01 2011-10-26 한미홀딩스 주식회사 (6ｒ)-3-헥실-4-히드록시-6-운데실-5,6-다이히드로피란-2-온의 제조방법 및 이에 사용되는 중간체
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
WO2010138338A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
KR101903354B1 (ko) 2009-06-17 2018-10-04 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
WO2012033846A1 (en) 2010-09-09 2012-03-15 Rutgers, The State University Of New Jersey Arylpropionyl-triketone antibacterial agents
US8772332B2 (en) * 2010-09-09 2014-07-08 Richard H. Ebright Arylpropionyl-alpha-pyrone antibacterial agents
WO2012037508A2 (en) 2010-09-17 2012-03-22 Rutgers, The State University Of New Jersey Antibacterial agents: high-potency myxopyronin derivatives
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
EP2651940A1 (en) 2010-12-16 2013-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
US9517994B2 (en) 2012-01-05 2016-12-13 Rutgers, The State University Of New Jersey Antibacterial agents: phloroglucinol derivatives
JP2015527403A (ja) * 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖプロテアーゼ阻害剤
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
ES2684755T3 (es) 2013-11-13 2018-10-04 Vertex Pharmaceuticals Incorporated Métodos para preparar inhibidores de la replicación de virus de la gripe
DK3068776T3 (da) 2013-11-13 2019-07-29 Vertex Pharma Inhibitorer af replikation af influenzavira
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015095265A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015138220A1 (en) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10450292B2 (en) 2015-12-10 2019-10-22 Rutgers, The State University of New Jersesy Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
US11993590B2 (en) * 2016-12-04 2024-05-28 712 North Inc. Pyranone compounds useful to modulate OMA1 protease
WO2019160873A1 (en) 2018-02-13 2019-08-22 Rutgers, The State University Of New Jersey Antibacterial agents: o-alkyl-deuterated pyronins
US12209082B2 (en) 2018-02-13 2025-01-28 Rutgers, The State University Of New Jersey Antibacterial agents: soluble salts and aqueous formulations of pyronins
US11572337B2 (en) 2018-03-06 2023-02-07 Rutgers, The State University Of New Jersey Antibacterial agents: arylalkylcarboxamido phloroglucinols
CN110551090B (zh) * 2019-10-21 2021-06-18 扬州工业职业技术学院 一种超声波提取中药狗脊中抗肿瘤活性成分的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
AU2023395972A1 (en) * 2022-12-16 2025-07-03 Tenvie Therapeutics, Inc. Compounds, compositions, and methods
CN116730993A (zh) * 2023-04-25 2023-09-12 浙江科技学院 一种替拉那韦中间体及替拉那韦的制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB193507A (en) 1921-11-25 1923-02-26 English Electric Co Ltd Improvements in and connected with hydraulic impulse turbines
NL80964C (enExample) * 1952-03-08
BE519956A (enExample) * 1952-05-16
US2723277A (en) * 1952-08-26 1955-11-08 Hoffmann La Roche Malonic acid derivatives and process for the manufacture thereof
US2872457A (en) * 1956-04-19 1959-02-03 Wisconsin Alumni Res Found Process for the preparation of 4-hydroxycoumarin derivatives
GB836740A (en) * 1956-04-25 1960-06-09 Bayer Ag Coumarin derivatives and their production
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1463767A (fr) * 1963-04-03 1966-07-22 Clin Byla Ets Dérivés de la coumarine et leur préparation
BE674997A (enExample) * 1965-01-13 1966-07-12
FR1559595A (enExample) * 1966-12-13 1969-03-14
US3489774A (en) * 1967-04-24 1970-01-13 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno) propionyl)-coumarin products
US3493586A (en) * 1969-01-23 1970-02-03 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno)-propionyl)pyrone products
JPS4823942B1 (enExample) * 1969-02-14 1973-07-17
US3764693A (en) * 1969-11-21 1973-10-09 Lipha A rodenticidal compositions containing 4-hydroxy coumarins
US3835161A (en) * 1972-10-24 1974-09-10 Realisations Scient S E Res C 3-substituted-4-hydroxy-coumarins
US3931235A (en) * 1972-12-18 1976-01-06 The Dow Chemical Company Process for preparing sulfur-containing hydroxy pyrones
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
NZ194557A (en) * 1979-08-17 1984-09-28 Merck & Co Inc Substituted pyranone derivatives;dihydroxy acids therefrom;pharmaceutical compositions
CA1171424A (en) * 1981-06-17 1984-07-24 Alvin K. Willard ( )-(4r, 6s) - (e)-6-[2-(4'fluro-3,3', 5-trimethyl- [l,l'-biphenyl]-2-yl)ethenyl]-3,4,5,6- tetrahydro-4-hydroxy-2h-pyran-2-one
JPS634652A (ja) * 1986-06-25 1988-01-09 Hitachi Ltd 半導体装置
AU1044088A (en) 1986-12-17 1988-07-15 Nippon Soda Co., Ltd. Heterocyclic compounds having triketo skeleton
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
WO1989007939A2 (en) * 1988-03-01 1989-09-08 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
WO1991004663A1 (en) * 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
AU6633490A (en) * 1989-10-27 1991-05-31 Upjohn Company, The Method for treating hiv and other retroviruses and compounds useful therefor
JPH03227923A (ja) 1990-01-30 1991-10-08 Sawai Seiyaku Kk ひと免疫不全ウイルス疾患処置剤
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
AU8612491A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds
US5378694A (en) * 1990-09-07 1995-01-03 Schering Corporation Acyl and alkoxy substituted quinolines
JPH07110853B2 (ja) * 1990-09-07 1995-11-29 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
AU1748792A (en) * 1991-04-04 1992-11-02 Upjohn Company, The Phosphorus containing compounds as inhibitors of retroviruses
AU2871592A (en) * 1991-10-11 1993-05-03 Du Pont Merck Pharmaceutical Company, The Cyclic ureas and analogues useful as retroviral protease inhibitiors
CA2121900A1 (en) * 1991-10-22 1993-04-29 Ernest E. Kun Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as anti-tumor and anti-retroviral agents
DE4308451A1 (de) * 1992-09-10 1994-04-14 Bayer Ag 3-Aryl-pyron-Derivate
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections

Also Published As

Publication number Publication date
IL129871A0 (en) 2000-02-29
CN1154642C (zh) 2004-06-23
CA2560489A1 (en) 1995-11-16
PL190540B1 (pl) 2005-12-30
NL300216I2 (nl) 2006-06-01
ATE236894T1 (de) 2003-04-15
MY149862A (en) 2013-10-31
AU2368699A (en) 1999-06-03
IL113567A (en) 2003-05-29
SK284407B6 (sk) 2005-03-04
PE23196A1 (es) 1996-06-07
NO964676D0 (no) 1996-11-05
RU2139284C1 (ru) 1999-10-10
US6169181B1 (en) 2001-01-02
EP0758327A1 (en) 1997-02-19
WO1995030670A3 (en) 1996-04-25
MX9605391A (es) 1997-12-31
AU718117B2 (en) 2000-04-06
ES2192201T3 (es) 2003-10-01
FR05C0047I2 (enExample) 2007-10-19
DE122006000014I2 (de) 2007-03-29
IL129871A (en) 2003-11-23
CN1329378C (zh) 2007-08-01
KR100445929B1 (ko) 2005-09-30
JP3883206B2 (ja) 2007-02-21
FI964441A0 (fi) 1996-11-05
PT758327E (pt) 2003-08-29
FI117387B (fi) 2006-09-29
EP0758327B1 (en) 2003-04-09
DE69530294T2 (de) 2003-12-24
NO964676L (no) 1997-01-06
HK1084667A1 (en) 2006-08-04
NL300216I1 (nl) 2006-04-03
US5852195A (en) 1998-12-22
PL317061A1 (en) 1997-03-03
CA2187523A1 (en) 1995-11-16
DK0758327T3 (da) 2003-07-28
CN1539825A (zh) 2004-10-27
KR970702858A (ko) 1997-06-10
CZ296515B6 (cs) 2006-04-12
CN1150424A (zh) 1997-05-21
WO1995030670A2 (en) 1995-11-16
CA2187523C (en) 2006-11-21
NZ285510A (en) 1998-03-25
BR9507615A (pt) 1997-09-09
CA2560489C (en) 2010-01-12
HUT77601A (hu) 1998-06-29
DE122006000014I1 (de) 2006-11-16
FI964441L (fi) 1996-11-05
CZ317296A3 (en) 1997-04-16
NO2006003I2 (no) 2008-10-20
SI0758327T1 (en) 2003-08-31
AU701965B2 (en) 1999-02-11
TW504507B (en) 2002-10-01
LU91220I2 (fr) 2006-04-10
CO4810313A1 (es) 1999-06-30
SK138496A3 (en) 1997-06-04
MY127701A (en) 2006-12-29
JPH09512821A (ja) 1997-12-22
HU9603074D0 (en) 1997-01-28
NO315799B1 (no) 2003-10-27
AU2462695A (en) 1995-11-29
DE69530294D1 (de) 2003-05-15
NO2006003I1 (no) 2006-03-13
HK1066796A1 (zh) 2005-04-01
HU228057B1 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
FR05C0047I2 (enExample)
MY119031A (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
NO953070D0 (no) 4-hydroksy-benzopyran-2-oner og 4-hydroksysykloalkyl[BÅpyran-2-oner anvendbare for behandling av retrovirusinfeksjoner
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
TR199700470A2 (xx) Sildenafilin haz�rlanmas� i�in proses.
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
NZ325235A (en) New phenylamidine derivatives, a process for preparing the same and their use as medicaments
AU8460791A (en) Compound, preparation and use
GB2055366B (en) 2-phenylimino-5-(2'-carboxyphenyl)-1,3,4-thiadiazol-4-ine derivatives useful as plant-growth regulating agents
AU4188700A (en) Pseudomycin natural products
ES2151820A1 (es) Herbicidas a base de derivados de 1,3-oxazin-4-ona, composiciones que los contienen y procedimiento para su preparacion.